Clinical trials: Ticagrelor
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, Interventional Cardiology
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events…
- Trial name
- LD-ASPIRIN (NCT04240834)
- Testing
- Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly
A randomized controlled, open label, multicenter trial with 1000 patients aged 70 years and older, presenting with Non-ST-elevation acute coronary syndrome.
- Conditions
- Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction
- Trial name
- POPular AGE (NCT02317198)
- Testing
- Clopidogrel, Ticagrelor or Prasugrel
- Where
- Netherlands
- Volunteers
- 1,011 people
- Sponsor
- St. Antonius Hospital
Ischemic Stroke
Ticagrelor Versus Clopidogrel in Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within the first 24 hours of first-ever ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS…
- Trial name
- NCT05553613
- Testing
- Ticagrelor 90 MG Oral Tablet, Clopidogrel tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Intracranial Aneurysm
Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia
Prospective, post-registration, interventional, randomized, in parallel groups, multicenter Eurasian clinical study of DERIVO®/DERIVO® mini Aneurysm Embolization Device, Europe-Asia
- Trial name
- NCT06400940
- Testing
- ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg)., combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
- Where
- Russia
- Volunteers
- 640 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Healthy
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
This is a Phase 2A, randomized, double-blind, placebo-controlled, single dose, sequential group study to evaluate the safety, tolerability, PK, and PD of PB2452 vs matching placebo with ticagrelor (with or without acetylsalicylic…
- Trial name
- NCT03928353
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Coronary Artery Disease, Stents
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
This study aimed to compare the efficacy and safety of P2Y12 inhibitor monotherapy versus extended dual antiplatelet therapy (DAPT) following 12-month of DAPT in patients undergoing percutaneous coronary intervention (PCI) with…
- Conditions
- Coronary Artery Disease, Stents, Atherosclerosis
- Trial name
- SMART-CHOICEII (NCT03119012)
- Testing
- Clopidogrel, Ticagrelor, Aspirin
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome Patients With Diabetes After PCI
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes.
- Trial name
- TIGER-diabetes (NCT04307511)
- Testing
- Ticagrelor, Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Tong Ren Hospital
Healthy
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the anti-platelet effects of ticagrelor as part of a…
- Trial name
- NCT04122170
- Testing
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion
- Where
- 15 sites in United States, Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
STEMI - ST Elevation Myocardial Infarction
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition.
- Trial name
- NCT06013020
- Testing
- NOAC+DAPT, DAPT
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Zunyi Medical College
Intracranial Aneurysm, Stent Complication
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm
The primary goal of the trial is to investigate whether the experimental arms (receiving the P2Y12 inhibitor Ticagrelor) compared with the control arm (taking dual antiplatelet therapy) could reduce bleeding complications in…
- Trial name
- SAC-TIDE (NCT06015477)
- Testing
- Ticagrelor monotherapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Unstable Angina
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
The purpose of this study is to evaluate differences in the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite in patients who received ticagrelor followed with methoxyflurane versus ticagrelor followed…
- Trial name
- METHANE (NCT04442919)
- Testing
- Ticagrelor followed with Methoxyflurane, Ticagrelor followed with Morphine, Ticagrelor alone
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Brain Disease, Vertebral Artery Stenosis
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral…
- Trial name
- NCT06301776
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 560 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
Healthy Subjects
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- TIC-025-23 (NCT06233266)
- Testing
- Ticagrelor-Test product, Ticagrelor-Reference product
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Coronary Artery Disease, Platelet Reactivity
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
Patients with Chronic Coronary Syndrome (CCS) undergoing with elective percutaneous coronary intervention (PCI) are treated with dual antiplatelet therapy (DAPT), consisting of aspirin combined with clopidogrel for 6 months.
- Trial name
- NCT05773989
- Testing
- CYP2C19 genotype guided P2Y12 monotherapy, Clopidogrel
- Where
- Netherlands
- Volunteers
- 88 people
- Sponsor
- St. Antonius Hospital
De Novo Stenosis, Coronary Artery Disease
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
Coronary restenosis has been one of the main reasons affecting the prognosis of patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI).
- Conditions
- De Novo Stenosis, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- CAGE-FREEIII (NCT05209412)
- Testing
- Lepu Paclitaxel coated balloon, Resolute Integrity Zotarolimus eluting stents, Aspirin
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Xijing Hospital
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without…
- Trial name
- NCT05162131
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Ischemic Stroke
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 300 mg clopidogrel were assessed through…
- Trial name
- NCT06120725
- Testing
- Ticagrelor 90 MG, Clopidogrel
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca